Searchable abstracts of presentations at key conferences in endocrinology

ea0035p2 | Adrenal cortex | ECE2014

Development of new improved derivatives of iodometomidate for the diagnosis of adrenocortical tumours and radiotherapy of adrenal carcinoma

Heinze Britta , Schirbel Andreas , Michelmann David , Nannen Lukas , Ries Martin , Thomas Elke , Gobel Heike , Allolio Bruno , Hahner Stefanie

Objective: We have developed (123/131I)iodometomidate (IMTO) for specific adrenal imaging and radiotherapy of adrenocortical carcinoma. IMTO binds with high affinity and specificity to the two adrenocortical enzymes aldosterone synthase (CYP11B2) and 11β-hydroxylase (CYP11B1). Metabolic analysis has revealed very rapid metabolization of IMTO both in vitro and in vivo by hepatic esterases. Due to the low metabolic stability of (123/131</su...

ea0070aep96 | Adrenal and Cardiovascular Endocrinology | ECE2020

Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS

Teresa Fuss Carmina , Brohm Katharina , Kurlbaum Max , Hannemann Anke , Kendl Sabine , Fassnacht Martin , Deutschbein Timo , Hahner Stefanie , Kroiss Matthias

Objective: The saline infusion test (SIT) is a standard confirmatory test for primary aldosteronism (PA) and based on impaired aldosterone suppression in PA compared to essential hypertension (EH). In the past, aldosterone was quantified using immunoassays (IA). Due to the more widespread use of liquid chromatography tandem mass spectrometry (LC-MS/MS) in clinical routine, we aimed at a method-specific aldosterone threshold for the diagnosis of PA during SIT and explored the d...

ea0070aep151 | Bone and Calcium | ECE2020

Cardiovascular status in chronic hypoparathyroidism – a single-center analysis in 133 patients compared to the general german population

Teresa Fuss Carmina , Gronemeyer Karen , Hermes Franca , Dörr Marcus , Koschker Ann-Cathrin , Nordbeck Peter , Hannemann Anke , Hahner Stefanie

Introduction: Even though it is well known that long-term complications, such as renal insufficiency and brain calcifications can occur in patients with hypoparathyroidism (HPT), the risk of cardiovascular diseases still remains unclear.Objective: To perform a systematic assessment of cardiovascular function in a well-characterized cohort of patients with HPT compared to population-based controls.Methods: 133 patients with chronic ...

ea0020p181 | Endocrine tumours and neoplasia | ECE2009

Steroidogenic factor 1 – a valuable diagnostic and prognostic tool in patients with adrenocortical carcinoma

Sbiera Silviu , Schmull Sebastian , Voelker Hans-Ullrich , Kraus Luitgard , Beuschlein Felix , Willenberg Holger , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: No immunohistochemical marker has yet been established to reliably differentiate adrenocortical tumors from other adrenal masses (e.g. metastases). Thus, a panel of several markers like melan A and inhibin is currently used for this purpose, but suffers from limited diagnostic accuracy. We hypothesized that expression of steroidogenic factor 1 (SF-1), a nuclear transcription factor involved in adrenal development and steroidogenesis, might hold significant diagnost...

ea0016p320 | Endocrine tumours | ECE2008

Mitotane induces a concentration-dependent impairment of platelet aggregation in patients with adrenocortical carcinoma

Hahner Stefanie , Eigenthaler Martin , Savvoukidis Theodoros , Johanssen Sarah , Wortmann Sebastian , Koschker Ann-Cathrin , Allolio Bruno , Fassnacht Martin

Standard treatment of adrenocortical carcinoma (ACC) comprises adrenolytic therapy with mitotane. Prolongation of bleeding time has previously been observed based on a series of 7 patients (Haak et al. 1991). As patients with ACC frequently undergo surgery for local recurrence or metastases, we have studied the effect of mitotane on coagulation in 44 patients with ACC before and/or during treatment with mitotane (total sample size n=62).Pla...

ea0014oc3.5 | Endocrine tumors &amp; neoplasia | ECE2007

[123I]Iodometomidate as a radiotracer for adrenal scintigraphy – first clinical experience

Hahner Stefanie , Stuermer Andrea , Fassnacht Martin , Kreissl Michael , Reiners Christoph , Beuschlein Felix , Zink Martina , Zolle Ilse , Schirbel Andreas , Allolio Bruno

Adrenal masses are highly prevalent tumours comprising of a variety of entities. Therefore, therapeutic consequences also vary considerably. The CYP11B-specific PET-tracer [11C]metomidate has been shown to be suitable to characterize adrenal lesions. However, its availability is restricted to PET-centers with an on-site cyclotron. Also imaging is hindered by the short tracer half-life (20 min). Therefore, we have developed [123I]iodometomidate as a tracer...

ea0056oc5.4 | Diving deep into adrenal cortex diseases | ECE2018

Assessment of Tissue Sodium Content by 23Na-MRI in Patients with Adrenal Insufficiency – a Pilot Study

Weng Andreas , Burger-Stritt Stephanie , Chifu Irina , Christa Martin , Petritsch Bernhard , Bley Thorsten , Kostler Herbert , Hahner Stefanie

Introduction: Patients with chronic primary adrenal insufficiency (PAI) depend on lifelong gluco- (GC) and mineralocorticoid (MC) replacement therapy. Reduced subjective well-being is however often described by these patients in absence of clinical or laboratory abnormalities and is thus a strong indicator of the gap between the concept of adequate hormone substitution and patients’ requirements. The aim of this study was to investigate the potential role of 23...

ea0098t11 | Trials In Progress | NANETS2023

NET RETREAT: a Phase II Study of 177Lutetium-Dotatate Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET

Chauhan Aman , O'Callaghan Chris , Myrehaug Sten , Bodei Lisa , Kunz Pamela , Dasari Arvind , Strosberg Jonathan , Alexander Stefanie , Cheung Winson , Singh Simron

Background: 177Lu-DOTATATE is an FDA and Health Canada-approved treatment option for metastatic, progressive GEPNET patients. 177Lu-DOTATATE is now often considered the treatment of choice for small bowel/midgut patients who have progressed on somatostatin analogs (SSA). Despite 177Lu- DOTATATE’s impressive disease stabilization, many patients will eventually progress. Progression after prior use of PRRT does not necessarily render these tumors resistant to future PRRT tr...

ea0041ep5 | Adrenal cortex (to include Cushing's) | ECE2016

Paradoxical worsening of lipid metabolism after successful treatment of primary aldosteronism

Adolf Christian , Asbach Evelyn , Dietz Anna , Hahner Stefanie , Quinkler Marcus , Rump Lars Christian , Bidlingmaier Martin , Treitl Marcus , Hallfeldt Klaus , Beuschlein Felix , Reincke Martin

Primary aldosteronism (PA) describes the most frequent cause of secondary arterial hypertension. Aldosterone itself represents a BP-independent cardiovascular risk factor associated with increased rates of morbidity and mortality. Recently a worsening of lipid metabolism after treatment has been described.Objective: Our aim was to analyse changes in lipid parameters according to treatment outcome in PA patients. Data of 215 consecutive PA patients with u...

ea0037oc1.3 | Adrenal 1 | ECE2015

[123/131I] azetidinylamide a novel radiotracer for diagnosis and treatment of adrenocortical tumours -- from bench to bedside

Hahner Stefanie , Heinze Britta , Herrmann Ken , Buck Andreas K , Blumel Christina , Hanscheid Heribert , Brumberg Joachim , Michelmann David , Nannen Lukas , Ries Martin , Fassnacht Martin , Allolio Bruno , Schirbel Andreas

Background: We have recently introduced [123/131I]iodometomidate (IMTO) which selectively binds to the adrenocortical enzymes aldosterone synthase and 11ß-hydroxylase as SPECT tracer. IMTO has been proven to be useful for molecular adrenal imaging and radiotherapy in adrenal cancer (ACC). As IMTO is rapidly inactivated by endogenous esterases which may impair target tissue to background activity and therapeutic efficacy, >50 new IMTO derivatives have been d...